Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/in Observational/by MaxEcDNA and Prostate Cancer: A New Frontier in Understanding Resistance
/in Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxNewsletter 4/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! I’m back on track. This past week was packed with new clinical trial information. I want to highlight the ever-increasing role of AI in drug discovery—we are truly living in a transformative time. As usual, we also have a […]
Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025